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Tuesday, February 23, 2010 505awithin 30 s after EGTA treatment. We conclude that NCX activity in ASMC is
much more susceptible to inactivation at high concentrations of Na (Na-depen-
dent inactivation) than in transfected CHO cells.
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Site directed mutagenesis has shown that Ser621 in the CBD2 sub-domain of the
Ca2þ-regulatory domain of scallop muscle Naþ - Ca2þ exchanger (NCX-SCA)
is a substrate for cAMP-PK (PK-A) in the native membrane - bound enzyme [1,
2], and under the same conditions Naþ-driven 45Ca2þ uptake is stimulated [3].
Examination of the amino acid sequence of NCX-SCA (AY567834, GenBank)
shows a consensus sequence for AMP-PK in CBD2 in the Ca2þ-regulatory
domain, with Ser621 as the target residue. The consensus sequence for
cAMP-PK in CBD2 (K618RGSV) is embedded within that for AMP-PK
(L616LKRGSVEDL). Exposure of native scallop muscle membranes to consti-
tutively active AMP-PK [4] activated Naþ - Ca2þ exchange by approximately
the same factor as with cAMP-PK. These results suggest that both intra- and
extracellular signals may stimulate the activity of NCX-SCA through phos-
phorylation of the Ca2þ-regulatory domain in the large cytoplasmic loop.
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The Naþ/Ca2þ exchanger (NCX1.1) plays the primary role in Ca2þ extrusion
from cardiac myocytes during diastole. There have been many reports showing
that NCX1.1 expression levels are elevated in heart failure; however, the im-
portance of NCX1.1 in the pathophysiology of cardiac disease is not well un-
derstood. To determine the in vivo cardiac function of NCX1.1, we generated
transgenic mouse lines with cardiac-specific overexpression of wild-type or
mutated NCX1.1, with Naþ-dependent inactivation eliminated. Here we
show that NCX1.1 mutant transgenic mice develop dilated cardiomyopathy,
whereas wild-type NCX1.1 transgenic mice produce hypertrophic cardiomyop-
athy. Six-month-old mutant transgenic mice showed contractile dysfunction,
ventricular arrhythmias, interstitial fibrosis, and mitochondrial defects. Cardiac
myocytes isolated from these mice showed reduced Ca2þ transients, suggesting
greater Ca2þ extrusion via overexpressed mutant exchangers. Microarray anal-
ysis of their ventricles clearly indicated molecular changes generally associated
with the heart disease phenotype. Thus, these mouse models will be useful for
understanding the role of NCX1.1 in cardiac diseases.
2617-Pos
Ibogaine Stimulates Ionic Currents Mediated by Serotonin Transporter
Wei Zhang, Zhen Tao, Joan Gesmonde, James R. Howe, Gary Rudnick.
Yale University, New Haven, CT, USA.
Ibogaine is a non-competitive inhibitor of serotonin transporter (SERT) that is
thought to stabilize a conformation of SERT in which the substrate binding site
is open to the cytoplasm. Cocaine is a competitive SERT inhibitor thought to sta-
bilize a conformation with the substrate site open to the extracellular medium. As
measured by whole-cell patch clamp, the substrate, serotonin (5-hydroxytrypta-
mine, 5-HT), induced inward currents in HEK-293 cells stably expressing
SERT. These currents were previously shown to be uncoupled from 5-HT flux.
Cocaine, like other previously tested competitive inhibitors, blocked this current
and also blocked a small leak current observed in the absence of 5-HT. Ibogaine,
in contrast to competitive inhibitors, stimulated an inward current in the absenceof 5-HT. This current was, like the 5-HT induced current, blocked by inhibitory
concentrations of cocaine. Concentrations of ibogaine that largely inhibited trans-
port stimulated smaller currents than did 5-HT, and those currents were slower to
develop than the 5-HT currents. When ibogaine was added after 5-HT, the current
decreased to the level observed with ibogaine alone. This decrease occurred with
a time course similar to the time course of the appearance of the ibogaine current
when ibogaine was added alone. These results suggest that SERT-mediated cur-
rents are associated with conformations of SERT that are different from the con-
formation stabilized by competitive inhibitors such as cocaine. Both ibogaine and
5-HT apparently alter SERT conformation and increase the proportion of trans-
porter conformations that mediate uncoupled ion permeation.
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The human serotonin transporter (SERT) regulates the concentration of seroto-
nin, a neurotransmitter, in the synaptic cleft through the reuptake of serotonin.
SERT is a member of SLC6 (Solute Carrier) family with 12 transmembrane he-
lices and two N-linked glycosylation sites. We synthesized the SERT gene
from 90 oligo DNAs by PCR-based gene assembly. After transient transfection
of the codon-optimized synthetic SERT gene to mammalian HEK293 cells and
single-step immunoaffinity purification using N-terminal Flag-tag, full-length
expression was confirmed by nano-ESI MS/MS analysis. Then, we constructed
a mammalian stable cell line which inducibly expresses the human SERT gene.
The glycosylation profile showed that the unglycosylated species expressed at
an early stage after tetracycline induction eventually decreased and glycosy-
lated species came to be dominant at a later stage (32hr or later). It turned
out that the N-linked glycosaccharides at N208 and N217 were deglycosylated
with PNGase F without denaturation, which implied that the N-linked glyco-
saccharides were well exposed. Blue Native PAGE showed that the purified
SERT was dominantly in a tetrameric state. It is consistent with a previously
published result of the dopamine transporter, other SLC6 family transporter.
We further investigated the functionality of SERT both at a cellular level
and in a purified form. HEK293 cells overexpressing the SERT on the plasma
membrane uptake the neurotransmitter analogues in time dependent manner.
Ligand binding assay with [3H] imipramine showed that the purified SERT
was fully functional and the functional expression level was determined as
mg level per litter culture volume. Those result shows that mammalian overex-
pression system along with the use of synthetic gene would be useful in eluci-
dating structure and function relationship of the human transporters.
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Malaria remains one of the most important diseases in developing countries.
Plasmodium falciparum (Pf), the etiological agent of malaria, is developing
an increasing resistance to traditional drugs, like chloroquine (CQ). Conse-
quently, the development of new antimalarial agents able to overcome CQ-
resistance is an urgent task to be accomplished.
The antifungal agent clotrimazole (CLT) has been shown to have a moderate
growth-inhibiting effect on differentPf strains (1), and it has been taken as a model
for the rational design of innovative classes of antimalarial agents (2). We have
previously shown that CLT is able to inhibit the SERCA1 (SR-CaATPase) (3).
Here we present some results concerning the effect on SERCA1 of NF1058 (4),
a novel compound with potent antimalarial properties that possesses key struc-
tural elements of both CLT and CQ. We used an approach that combines bio-
chemical and electrical techniques. Our data show that NF1058 inhibits the
steady-state hydrolytic activity of the pump with a medium affinity (K0.5 ¼
41 5 1 microM), but it does not interfere with Ca-binding to the enzyme.
We therefore suggest that the reduction of steady-state hydrolytic activity of
SERCA1 by NF1058 may be due to an interference with the Ca-release process.
We are planning to explore the possibility that NF1058 can inhibit PfATP6,
a SERCA-type ATPase expressed by the plasmodium.
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